Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.

The SURMOUNT-OSA master protocol comprised two, 52-week, randomized, double-blind, placebo-controlledphase 3 studies (study 1 and study 2) and demonstrated a significant reduction of a number of cardiometabolic risk measures in participants with OSA and obesity following treatment with tirzepatide.

SURMOUNT-OSA综合方案包括两项为期52周的随机、双盲、安慰剂对照的3期研究（研究1和研究2），并在接受tirzepatide治疗的OSA和肥胖患者中显示出显著减少多项心代谢风险指标。

Here we report prespecified analysis of cardiometabolic risk measures in SURMOUNT-OSA.

在这里，我们报告了SURMOUNT-OSA研究中预先设定的心血管代谢风险指标分析。

Post hoc analyses include changes in a homeostatic model assessment for insulin resistance and mediation analysis to determine the proportion of observed changes attributable to reductions in body weight, apnea-hypopnea index and sleep apnea-specific hypoxic burden.

事后分析包括胰岛素抵抗稳态模型评估的变化以及介导分析，以确定观察到的变化中有多少比例可归因于体重减轻、呼吸暂停低通气指数和睡眠呼吸暂停特异性缺氧负荷的减少。

In both study 1 and study 2 of SURMOUNT-OSA, tirzepatide treatment was associated with greater alleviation of cardiometabolic risk factors than placebo.

在SURMOUNT-OSA研究1和研究2中，tirzepatide治疗与安慰剂相比，与更大的心血管代谢风险因素缓解相关。

Independent mediation effect of changes in OSA metrics was observed on high-sensitivity C-reactive protein, homeostatic model assessment for insulin resistance and triglycerides.

独立的OSA指标变化对高敏C反应蛋白、胰岛素抵抗的稳态模型评估和甘油三酯的中介效应被观察到。

The combination of changes in weight and OSA metrics, as well as weight alone, had a significant mediation effect on systolic blood pressure, but there was no significant mediation effect of weight or OSA metrics observed on diastolic blood pressure.

体重和睡眠呼吸障碍（OSA）指标的变化组合，以及仅体重本身，对收缩压有显著的中介效应，但对舒张压的体重或OSA指标没有观察到显著的中介效应。

Based on the mediation analysis, treating both sleep-disordered breathing and obesity is likely required to optimize the treatment effect on cardiometabolic benefits for patients with moderate-to-severe OSA and obesity.

基于中介分析，治疗睡眠呼吸障碍和肥胖可能是优化中重度OSA和肥胖患者心代谢益处治疗效果的必要条件。

The ClinicalTrials.gov registration number for this study is NCT05412004 .

本研究的ClinicalTrials.gov注册号为NCT05412004。